Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01442402 · ClinicalTrials.gov registry record
APOL1 Gene Variants in African American Kidney Transplant Recipients
A clinical trial, sponsored by Brigham and Women's Hospital.
- Terminated
- Registry status
- 39
- Enrollment target
NCT01442402: Clinical Trial study, sponsored by Brigham and Women's Hospital.
NCT01442402 is a clinical trial that was terminated before completion, run by Brigham and Women's Hospital. The registered enrollment target is 39 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01442402 was terminated before completion, sponsored by Brigham and Women's Hospital.
- TERMINATED
- Registry status
- 39 participants
- Enrollment target
Study Summary
Aim 1: Determine if there is an association between the APOL1 risk variants and allograft survival and function in African Americans Aim 2: Determine if there is an association between the presence of APOL1 risk variants in an African American kidney transplant recipient and the risk of recurrent disease Aim 3: Investigate mechanisms of APOL1 associated kidney disease by prospectively following African American kidney transplant recipients throughout their clinical course.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2014-04 |
| Est. Completion | 2014-04 |
Why NCT01442402 stopped before completion
NCT01442402 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 39 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT01442402 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01442402 about?
NCT01442402 is a clinical study titled "APOL1 Gene Variants in African American Kidney Transplant Recipients". Aim 1: Determine if there is an association between the APOL1 risk variants and allograft survival and function in African Americans Aim 2: Determine if there is an association between the presence of APOL1 risk variants in an African American kidney transplant recipient and the risk of recurrent...
What is the current status of trial NCT01442402?
This trial is currently terminated. The enrollment target is 39 participants. The study started on 2014-04. Estimated completion is 2014-04.
Who is sponsoring clinical trial NCT01442402?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03465592 · 39 participants · Phase 1
Trial of Nivolumab Following Partially Human Leukocyte Antigen (HLA) Mismatched BMT in Children & Adults With Sarcoma
- NCT03961776 · 39 participants
Monitoring Treatment Response With On-board DWI During Neo-adjuvant Chemo-radiation for Rectal Cancer Using Magnetic Resonance-guided-radiotherapy Systems
- NCT04050280 · 39 participants · Phase 2
CLAG-GO for Patients With Persistent, Relapsed or Refractory AML
- NCT04190862 · 39 participants · Phase 1
E-CEL UVEC as an Adjunct Cell Therapy for Treatment of Anal Fistulas
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia